Long-term subcutaneous treprostinil (Remodulin) therapy for severe pulmonary arterial hypertension

被引：0
|
作者：
Skoro-Sajer, N.
Bonderman, D.
Harja, E.
Jakowitsch, J.
Maurer, G.
Kneussl, M.
Lang, I. M.
机构：
[1] Vienna Gen Hosp, Dept Cardiol, Vienna, Austria
[2] Wilhelminenspital Stadt Wien, Vienna, Austria
来源：
EUROPEAN HEART JOURNAL | 2005年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P595
引用
收藏
页码：79 / 79
页数：1
相关论文
共 50 条
  • [21] Long-term treprostinil in pulmonary arterial hypertension: is the glass half full or half empty?
    Provencher, S.
    EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (06) : 1073 - 1075
  • [22] Long-Term Treatment of Pulmonary Arterial Hypertension with Treprostinil in Patient with Eisenmenger and Down Syndromes
    Gasior, Z.
    Sikora-Puz, A.
    Banska-Kisiel, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [23] Long-term subcutaneous treprostinil therapy evokes both survival benefits and continuous dose-dependent efficacy improvements in patients with pulmonary arterial hypertension
    Vachiery, JL
    Gautier, MT
    Huez, S
    Retailleau, K
    Naeije, R
    CIRCULATION, 2003, 108 (17) : 400 - 400
  • [24] Clinical and hemodynamic impact of subcutaneous (SQ) treprostinil (Remodulin®) in the management of pulmonary arterial hypertension (PAH):: Single-center experience
    Soto, Francisco J.
    Jain, Priyank
    Kleczka, James
    Siegel, Ronald
    Woods, Timothy
    Marks, David
    Presberg, Kenneth
    CHEST, 2006, 130 (04) : 120S - 120S
  • [25] Upfront triple combination therapy with ambrisentan, tadalafil and subcutaneous treprostinil in incident patients with severe pulmonary arterial hypertension
    D'Alto, M.
    Romeo, E.
    Argiento, P.
    Badagliacca, R.
    Papa, S.
    Farro, A.
    Sarubbi, B.
    Russo, M. G.
    Vizza, C. D.
    Golino, P.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3037 - 3037
  • [26] Long-term tolerability, side effects, dosing regimens and survival with first-line subcutaneous treprostinil for severe pulmonary hypertension
    Sadushi-Kolici, R.
    Skoro-Sajer, N.
    Bonderman, D.
    Martischnig, A.
    Schemper, M.
    Klepetko, W.
    Glatz, J.
    Jakowitsch, J.
    Lang, I. M.
    EUROPEAN HEART JOURNAL, 2010, 31 : 764 - 764
  • [27] Long-term safety and survival time under subcutaneous treprostinil treatment in patients with severe chronic thromboembolic pulmonary hypertension (CTEPH)
    Jansa, Pavel
    Sadushi-Kolici, Roela
    Kopec, Grzegorz
    Skoro-Sajer, Nika
    Halank, Michael
    Simkova, Iveta
    Steringer-Mascherbauer, Regina
    Salobir, Barbara
    Klepetko, Walter
    Lindner, Jaroslav
    Lang, Irene M.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [28] Gallbladder polyps in patients receiving subcutaneous treprostinil therapy for Pulmonary Arterial Hypertension.
    Cullivan, S.
    Boyle, N.
    Mc Cullagh, B.
    Gaine, S. P.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 1) : S34 - S35
  • [29] Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
    White, R. James
    Parikh, Keyur
    Allen, Roblee
    Feldman, Jeremy
    Jerjez-Sanchez, Carlos
    Pan, Lei
    Keogh, Anne
    Vizza, C. Dario
    Shapiro, Shelley
    Gordon, Kathryn
    Broderick, Meredith
    Bartolome, Sonja
    PULMONARY CIRCULATION, 2020, 10 (04)
  • [30] Long-term sitaxsentan therapy in Pulmonary Arterial Hypertension (PAH)
    Horn, E
    Langleben, D
    Frost, A
    Hill, N
    McLaughlin, V
    Oudiz, R
    Dixon, RAF
    Barst, RJ
    EUROPEAN HEART JOURNAL, 2004, 25 : 466 - 466
12345